Comparison of efficacy and safety of two modes of Autologous Serum Therapy injectio
Phase 3
- Conditions
- Health Condition 1: L501- Idiopathic urticaria
- Registration Number
- CTRI/2024/02/062280
- Lead Sponsor
- Mythraye B
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients of age above 18 years clinically diagnosed
with chronic spontaneous urticaria and giving consent to participate in the
study.
Exclusion Criteria
Pregnant and lactating women, immunocompromised
patients, those on immunosuppressants for other illness
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1.To compare the efficacy of subcutaneous autologous serum therapy versus intramuscular autologous serum therapy by Urticaria Activity Score (UAS7), Total Urticaria Severity Score (TSS) and Urticaria Control Test (UCT). <br/ ><br>2. To compare the tolerability of subcutaneous autologous serum therapy versus <br/ ><br>intramuscular autologous serum therapy by likert scale.Timepoint: UAS7, TSS and UCT scores will be measured at baseline, 4th week, 9th week (end of treatment) and 12th week (follow up)
- Secondary Outcome Measures
Name Time Method Estimation of proportion of patients having anti-thyroid peroxidase antibody (TPO) in patients with chronic spontaneous urticaria.Timepoint: At baseline